Liftstream is an executive search recruitment company in the life sciences sector
PTC Therapeutics appoints Chief Medical Officer and communicates CHMP conditional decision
Authored by Karl Simpson
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Ariad, Ataluren, Chief Medical Officer, CHMP, DMD, Duchenne, Duchenne Muscular Dystrophy, EMA, europe, GSK, Iclusig, investors, MAA, market authorisation application, Murad Husain, oncology, parents, patients, phase III clinical trial, Prosensa, PTC Therapeutics, Rober J. Spiegel, Sarepta, USA, VP Global Regulatory Affairs
Leave a comment
Prosensa, Sarepta, PTC, Summit and DART all contribute to the ubiquity of news in Duchenne
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Amsterdam Biotech, Ataluren, Charity, clinical, DART Therapeutics, DMD, Drisapersen, Duchenne Muscular Dystrophy, Eteplirsen, FDA, Gene Williams, Glynn Edwards, GSK, GSK/Prosensa, HT-100, IPO, Market Access, NASDAQ, Netherlands, Orphan drugs, Oxford Biotech, phase II studies, Priority Review, Prosensa, PTC Therapeutics, Rare Disease, regulatory affairs, research and development, Sarepta Therapeutics, Save our Sons, SMT C1100, Summit plc, UK, USA, Utrophin, utrophin modulation
2 Comments
Biotech IPO fever spreads from West to East
Authored by Karl Simpson
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged Ataluren, Biopolis, cardiomyocytes, derived neurons, DMD, Duchenne Muscular Dystrophy, Human iPSC, Institute of Medical Sciences, IPO, Japan, JASDAQ, Kyoto University, Malaysia Biotech, New Zealand Biotech, Prof. Hiromitsu Nakauchi, Prof. Norio Nakatsuji, PTC Therapeutics, ReproCELL, Stem Cell, University of Tokyo
Leave a comment
PTC Therapeutics opts for conditional approach in Duchenne
Authored by Paul Foster
Posted in Orphan Drugs and Rare Diseases
Tagged Allan Jacobson, AstraZeneca, Ataluren, celgene, Cystic Fibrosis, DMD, DNA, Duchenne Muscular Dystrophy, EMA, FDA, Genzyme, Gilead, Liftstream Rare Disease Day, MAA, Marketing Authorisation Application, Merck, Orphan Drug, Pfizer, PTC Therapeutics, Rare Disease, rare disease day, RDD13, Stuart W. Peltz
Leave a comment